Latest Breaking News On - Spain intensity - Page 8 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis Axogen, Inc.February 18, 2021 GMT ALACHUA, Fla., Feb. 18, 2021 (GLOBE NEWSWIRE) Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of pilot phase analysis for its REPOSE clinical study.  Analysis of the REPOSE study’s 15-subject single arm pilot phase demonstrated that subjects experienced a clinically significant reduction in pain from baseline at each of the 3, 6, 9, and 12 month timepoints following surgical excision of the neuroma and placement of Axoguard Nerve Cap® (p 0.0001). Specifically, the study observed a mean reduction in pain of 69 points at 3 months and 80 points at 12 months as measured on the 100-point Visual Analog Scale (VAS). Additionally, subjects experienced clinically m

United statesUnited kingdomSouth koreaPeter marianiCraig thomajanKaren zaderejExchange commissionAxogen incAxoguard nerve capVisual analog scalePhysical functionSleep disturbancePain interferenceSpain intensitySpain behaviorPeripheral nerve surgeon